Lifileucel (LN-144), a one-time autologous TIL therapy developed by Iovance Biotherapeutics, demonstrated an ORR of 31.4%, with 8 CRs and 40 PRs following a single infusion and up to six doses of HD IL-2 in a phase II C-144-01 trial of 153 patients with heavily pretreated advanced melanoma. This evidence concerns the gene IL2 and melanoma.